Back to Agenda
Session 7: Blockchain
Session Chair(s)
Adama Ibrahim, MBA
Vice President, Digital Strategy and Change Management
Novo Nordisk, United Kingdom
Aji Barot
Director, Global Commercial Development
Market Access Transformation, United Kingdom
Blockchain technology increases security and speeds up the exchange of information in a way that is cost-effective and more transparent. This technology has been increasingly used and considered in the healthcare sector as it can be applied to several aspects of the drug discovery and development lifecycle, namely data management, clinical trials, supply chain compliance, among many others. At this session, you will hear key stakeholders and users of Blockchain in Drug Development discussing challenges, risks and benefits.
Speaker(s)
The Patient Advocate Perspective
Jeanne Barnett
CysticFibrosis.com, United States
Pathfinder for Patients and Caregivers, Teacher, CEO/Founder
Diversity and Inclusion, Entrepreneur and Ex-Regulator Perspective
Yusuf Henriques, MPH
IndyGeneUS AI, United States
Founder and CEO
Blockchain Industry, Consortia and Consensys roadmap
Sean Manion, PhD
Equideum Health, United States
Chief Scientific Officer and FNO Coordination Lead
Blockchain Industry – Working with Hospitals during a Pandemic
Jim Nasr, MBA
ACOER and Ex-CDC, United States
Founder and Chief Executive Officer
The Clinician Perspective
Mathew Rose, MD, MS, MSc
SAAVHA Inc., United States
Founder and Chief Executive Officer
Have an account?